cimb-logo

Journal Browser

Journal Browser

Early Molecular Diagnosis and Comprehensive Treatment of Tumors, 2nd Edition

A special issue of Current Issues in Molecular Biology (ISSN 1467-3045). This special issue belongs to the section "Molecular Medicine".

Deadline for manuscript submissions: 31 October 2026 | Viewed by 87

Special Issue Editor

Special Issue Information

Dear Colleagues,

Timely and accurate diagnosis is crucial in improving cancer prognosis and guiding effective treatment strategies. This Special Issue will focus on the latest advancements in early molecular diagnostics and comprehensive treatment approaches in tumors. We aim to highlight innovative techniques, including liquid biopsy, next-generation sequencing (NGS), and novel biomarkers, that enhance early cancer detection and risk assessment.

Additionally, this Special Issue will explore integrative treatment modalities, combining targeted therapy, immunotherapy, precision medicine, and conventional approaches such as surgery, radiation, and chemotherapy. There will be a focus on the tumor microenvironment, the molecular mechanisms driving tumor progression, and emerging therapeutic strategies designed to improve patient outcomes.

By bringing together cutting-edge research and clinical applications, this Special Issue will provide a deeper understanding of tumor biology and pave the way for more effective personalized cancer treatments.

You can read the publications in the first volume here: https://www.mdpi.com/journal/cimb/special_issues/R8WT7615B6

Dr. Chan-Yen Kuo
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Issues in Molecular Biology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • next-generation sequencing (NGS)
  • novel biomarkers
  • precision medicine
  • targeted therapy
  • immunotherapy
  • integrative treatment
  • personalized cancer treatment

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers

This special issue is now open for submission.
Back to TopTop